EMEA-002296-PIP01-17-M02
Key facts
Invented name |
Alunbrig
|
Active substance |
brigatinib
|
Therapeutic area |
Oncology
|
Decision number |
P/0483/2020
|
PIP number |
EMEA-002296-PIP01-17-M02
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Takeda Pharm A/S
E-mail: paediatrics@tgrd.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|